ACA vs LSTR

The company exhibits a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm safety from distress. Despite strong recent earnings growth (YoY EPS +71.4%, Earnings Growth YoY +335.3%) and solid revenue momentum (24.60% YoY), elevated valuation metrics (P/E 38.61 vs. sector avg 55.59) and bearish insider activity weigh on near-term outlook. The stock trades significantly above the Graham Number of $59.01, suggesting overvaluation for defensive investors, though growth investors may justify the premium. Analysts maintain a strong_buy consensus, but insider selling and modest dividend strength temper enthusiasm.

LSTR exhibits a severe valuation disconnect, trading at $168.27 despite a Graham Number of $41.71 and an Intrinsic Value of $23.17. While the Piotroski F-Score of 4/9 indicates stable financial health and the low Debt/Equity ratio (0.17) provides a safety buffer, these are overshadowed by crashing fundamentals. With YoY earnings growth at -46.50% and revenue declining, the current P/E of 50.84 is unsustainable. The bearish technical trend (10/100) and analyst target price ($152.27) further suggest significant downside risk.